Industrial and labor consulting services, Urban planning and consulting services, Business services, nec, nec
Reveragen Biopharma, Inc.
ReveraGen BioPharma, Inc. is a biopharmaceutical company based in Silver Spring, MD, specializing in the development of innovative therapies for Duchenne muscular dystrophy (DMD) and other related indications. Their flagship product, AGAMREE (vamorolone), has received approval from both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), making it the first therapy for DMD to achieve dual approval. With a focus on venture philanthropy, ReveraGen BioPharma is dedicated to making a positive impact by applying advancements in steroid chemistry, pharmacodynamic biomarkers, clinical trial design, and business models to their drug development process. Driven by a commitment to return to non-profits and their constituents, ReveraGen BioPharma is at the forefront of research and clinical trials for DMD. Their groundbreaking work has demonstrated the efficacy of vamorolone in treating DMD, while also highlighting its safety advantages over traditional medications like prednisone. Through strategic partnerships and a dedication to innovation, ReveraGen BioPharma is revolutionizing the treatment landscape for DMD and paving the way for potential applications in other indications.Generated from the website